Drug intelligence / Profile preview

124I-labeled anti-amyloid mAb 11-1F4

Development stage: Phase 1
Lead developer: University of Tennessee
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

124I-labeled anti-amyloid mAb 11-1F4 is a radioiodinated monoclonal antibody used for imaging and detecting amyloid deposits in patients with systemic light chain (AL) amyloidosis. The antibody binds specifically to a conformational neoepitope contained within the first 18 amino acids of misfolded human immunoglobulin light chains. When labeled with the positron-emitting isotope 124I, it can be used for positron emission tomography-computed tomography (PET/CT) imaging to visualize amyloid deposits in patients. The antibody retains its immunoreactivity after radioiodination and has shown specific localization to amyloid deposits in experimental models. The unlabeled version of this antibody (11-1F4, later designated as CAEL-101 or anselamimab) has demonstrated the ability to promote phagocytic destruction and clearance of amyloid deposits.

Other names: 124I-labeled amyloid-reactive monoclonal antibody murine 11-F4

Targets

Conformational neoepitope of misfolded human immunoglobulin light-chain amyloid fibrils

Beyond the preview

Go deeper on 124I-labeled anti-amyloid mAb 11-1F4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 124I-labeled anti-amyloid mAb 11-1F4.

Explore the full profile